5 research outputs found
The Platelet as an Immunomodulator: The Old Thespian with New Roles in Atherosclerosis, Sepsis and Autoimmune Disease
Clinical Study Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles
Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated ( = 17) or untreated ( = 12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C ( < 0.05) and lower values of Lp-A-I:A-II ( < 0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB ( < 0.05), Lp-A-II:B:C:D:E ( < 0.05), Lp-B:E + Lp-B:C:E ( < 0.05), Lp-B:C ( < 0.05), and Lp-A-I ( < 0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670
Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles
Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n=17) or untreated (n=12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P<0.05) and lower values of Lp-A-I:A-II (P<0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P<0.05), Lp-A-II:B:C:D:E (P<0.05), Lp-B:E + Lp-B:C:E (P<0.05), Lp-B:C (P<0.05), and Lp-A-I (P<0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine.
COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
COVID-19 is also manifested with hypercoagulability, pulmonary
intravascular coagulation, microangiopathy, and venous thromboembolism
(VTE) or arterial thrombosis. Predisposing risk factors to severe
COVID-19 are male sex, underlying cardiovascular disease, or
cardiovascular risk factors including noncontrolled diabetes mellitus or
arterial hypertension, obesity, and advanced age. The VAS-European
Independent Foundation in Angiology/Vascular Medicine draws attention to
patients with vascular disease (VD) and presents an integral strategy
for the management of patients with VD or cardiovascular risk factors
(VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary
health care network for patients with VD-CVR for identification of
patients with VD-CVR in the community and patients' education for
disease symptoms, use of eHealth technology, adherence to the
antithrombotic and vascular regulating treatments, and (2) close medical
follow-up for efficacious control of VD progression and prompt
application of physical and social distancing measures in case of new
epidemic waves. For patients with VD-CVR who receive home treatment for
COVID-19, VAS recommends assessment for (1) disease worsening risk and
prioritized hospitalization of those at high risk and (2) VTE risk
assessment and thromboprophylaxis with rivaroxaban, betrixaban, or
low-molecular-weight heparin (LMWH) for those at high risk. For
hospitalized patients with VD-CVR and COVID-19, VAS recommends (1)
routine thromboprophylaxis with weight-adjusted intermediate doses of
LMWH (unless contraindication); (2) LMWH as the drug of choice over
unfractionated heparin or direct oral anticoagulants for the treatment
of VTE or hypercoagulability; (3) careful evaluation of the risk for
disease worsening and prompt application of targeted antiviral or
convalescence treatments; (4) monitoring of D-dimer for optimization of
the antithrombotic treatment; and (5) evaluation of the risk of VTE
before hospital discharge using the IMPROVE-D-dimer score and prolonged
post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH